CSIR has entered into an agreement with a Mumbai-based bio-pharma company to develop PEGylated Streptokinase (its patented ‘clotbuster’) for treatment of Ischemic Stroke.
Ischemic stroke:
Ischemic stroke occurs when a blood vessel carrying blood to the brain is blocked by a blood clot. This causes blood not to reach the brain.
High blood pressure is the most important risk factor for this type of stroke.
An ischemic stroke can occur in two ways.
Embolic stroke: Happens when a blood clot forms somewhere in the body (usually the heart) and then travels to the brain.
Thrombotic stroke: It is caused by a blood clot that forms inside one of the arteries supplying blood to the brain.
Ischemic strokes account for about 87% of all strokes.
The prevalence of these brain stroke is much higher in India than the West.
PEGylated Streptokinase:
The clotbuster (PEGylated Streptokinase - a novel biological entity) was invented by a team of scientists at CSIR-Institute of Microbial Technology (IMTECH), Chandigarh.
The CSIR-IMTECH and Epygen Biotech Pvt. Ltd. (a Mumbai based bio-pharmaceutical company) have entered into an agreement for the latter to develop the PEGylated Streptokinase for treatment of ischemic stroke.
By this Epygen has become the first company in India with exclusive licence for developing it.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
